2. Disease Areas
  3. Musculoskeletal and Skin Disease
  4. Muscle Disease
  5. Muscular Dystrophy

Muscular Dystrophy

Muscular dystrophy is a group of over 30 genetic disorders characterized by progressive weakness and degeneration of skeletal muscles, caused by defects in protective proteins that lead to muscle fiber damage, degeneration, and eventual loss of function. Symptoms vary widely in age of onset, severity, and muscle involvement, with all forms progressively worsening over time. Some types also affect cardiac muscle, potentially leading to heart failure. The condition is not contagious or injury-induced, and clinical features may overlap with other myopathies such as congenital myopathy and spinal muscular atrophy, complicating diagnosis. In animals, a similar syndrome can result from nutritional deficiencies in vitamin E or selenium, manifesting as cardiac and musculoskeletal abnormalities, including myocardial lesions with hyaline degeneration and necrosis.

Muscular Dystrophy (6):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-130687A
    Psicose 23140-52-5 99.90%
    Psicose (DL-Psicose) is an orally effective sugar substitute. Psicose activates the PI3K/Akt/mTOR pathway to promote muscle synthesis. Psicose upregulates IGF-1 and downregulates Myostatin. Psicose normalizes mitochondrial dysfunction by increasing G6P activity. Psicose enhances the activity of antioxidant enzymes and reduces oxidative stress markers. Psicose increases muscle mass, grip strength and muscle weight in aged mice and diet-induced obese mice. Psicose improves obesity and type 2 diabetes. Psicose can be used in the research of age-related sarcopenia.
    Psicose
  • HY-W074912
    (S)-2-Amino-5,5,5-trifluoropentanoic acid 122565-28-0
    (S)-2-Amino-5,5,5-trifluoropentanoic acid ((S)-5,5,5-Trifluoronorvaline; H-Nva (5,5,5-triF)-OH) is a selective Sestrin-GATOR2 modulator that indirectly inhibits mTORC1 activity via a competitive binding mechanism. (S)-2-Amino-5,5,5-trifluoropentanoic acid can be used in research on cancer, metabolic diseases, neurodegenerative diseases, and muscle atrophy.\n
    (S)-2-Amino-5,5,5-trifluoropentanoic acid
  • HY-182062
    NAMPT activator-9 931366-46-0
    NAMPT activator-9 (Compound DIPM) is an allosteric, non-competitive NAMPT activator, with an EC50 of 3.366 μM against hNAMPT. NAMPT activator-9 enhances the enzymatic activity of NAMPT via an allosteric, non-competitive mechanism. NAMPT activator-9 increases intracellular NAD+ levels. NAMPT activator-9 restores myotube diameter and reduces the expression of atrophy markers Atrogin-1 and MuRF1. NAMPT activator-9 is applicable to research related to muscle atrophy.
    NAMPT activator-9
  • HY-P11741
    BV2
    BV2 is a delivery peptide that binds to BVES, with a Ka of 2.03 μM for the BVES target. BV2 specifically binds to the extracellular domain of BVES, achieving muscle homing and cellular internalization via caveolae-mediated endocytosis. When BV2 is modified on the surface of exosomes by PMO, it enhances dystrophin restoration in the peripheral muscles and myocardium of dystrophin-deficient mice. BV2 is applicable to research related to Duchenne muscular dystrophy and muscle atrophy.
    BV2
  • HY-N12489
    Ishophloroglucin A 2263882-48-8
    Ishophloroglucin A is an orally active phlorotannin compound found in Ishige okamurae. Ishophloroglucin A can alleviate Dexamethasone (HY-14648)-induced muscle atrophy through muscle protein metabolism. Ishophloroglucin A can improve impaired protein synthesis (PI3K and Akt) or degradation (muscle-specific ubiquitin ligase muscle RING finger and atrogin-1). Ishophloroglucin A can be used for research of muscle atrophy-related diseases.
    Ishophloroglucin A
  • HY-181619
    TAO Kinase-IN-3 3114565-22-6
    TAO Kinase-IN-3 is a potent pan-TAOK (Thousand-And-One Kinase) inhibitor that specifically binds to and inhibits the kinase activities of TAOK1, TAOK2 and TAOK3 with Kd values of <0.17 nM, 0.34 nM, and 0.17 nM, respectively. TAO Kinase-IN-3 can be used to study Alzheimer's disease, primary tauopathies and related syndromes. In addition, TAO Kinase-IN-3 is also widely used in research on the mechanisms of cancer cachexia and the muscle atrophy it induces.
    TAO Kinase-IN-3